HO173: EVOLVE-1

About this trial

Participants receive the current standard treatment of ivosidenib and azacitidine, together with either venetoclax or a placebo (a treatment with no active drug). The study looks to determine whether adding venetoclax improves survival, increases remission rates, reduces the amount of remaining leukemia in the body, and provides better overall outcomes for patients who are unable to receive intensive chemotherapy.

Patient Profile

Adults aged 18 years or older who have newly diagnosed AML and has not yet received treatment for it. Their leukemia has a specific genetic change called an IDH1 mutation, and because of their age, general health, or other medical conditions, standard intensive chemotherapy is not considered the best treatment option for them.

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, University Hospital Galway, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	HO173: EVOLVE-1
Number:	24-91
Full Title:	Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/​AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1)

Principal Investigator:	Dr. Janusz Krawczyk
Type:	Collaborative
Sponsor:	HOVON
Recruitment Started:	Global: Sept 2025 Ireland: April 2026

Global Recruitment Target:	227
Ireland Recruitment Target:	12